 Anika Therapeutics NASDAQ:ANIK was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage currently has a 37.00 price objective on the biotechnology companys stock. Zacks Investment Researchs price target would indicate a potential upside of 11.41 from the ... 